# Forensic Dossier: Study Forensics: Novel cholesterol drug dramatically lowers LDL but cardiovascular outcomes unknown

**Run ID:** `ocfix_study-forensics-032_Claude_Sonnet_62ed38`  
**Task:** study-forensics-032 | study_forensics | medium | study_forensics  
**Timestamp:** 2026-04-08T17:27:23.839882+00:00  
**Task Family:** overclaim  
**Trap Type:** surrogate_endpoint_overclaim  
**Ambiguity:** low  

## Executive Summary

**Agents tested:** Claude Sonnet
**Winner:** Claude Sonnet — **69.0/100** (margin: 0.0)
**Failure modes:** decorative_uncertainty, missed_key_insight
**Forensic flags:** 1
**Consistency findings:** 7
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Sonnet | 30.0/30 | 2.4/8 | 5.3/8 | 3.9/6 | 3.3/6 | 4.5/6 | 1.6/8 | 8.0/8 | 0.0/10 | 10.0/10 | **69.0/100** |

## Study Forensics Audit

### Claude Sonnet

**Classification:** `overclaim` [+] (gold: `overclaim`)
**Finding Recall:** 50%
**Matched Findings:** conclusion_exceeds_results
**Missed Findings:** unsupported_generalization
**Extra Findings:** evidence_matches_claim

## Reasoning Integrity Audit

### Claude Sonnet
**Classification:** Correct and well-supported
**Load-bearing steps:** 1 / 6

## Mechanism Analysis

### Claude Sonnet
| Aspect | Status |
|--------|--------|
| Concept named | :x: none |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** concept not named, mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Sonnet
Conclusion claims: 1
- Direct support: 0
- Indirect support: 1
- Unsupported: 0
- Contradicted: 0


## Forensic Flags

### Claude Sonnet

- **[MODERATE]** `weak_mechanism`: Correct answer but weak mechanism explanation — answer may not generalize
  - `final_answer`: "overclaim"


## Evidence Map

### Claude Sonnet

**Correctness:** 30.0/30
  - (+) `final_answer`: "overclaim"
    _Agent's answer for correctness check_
  - Note: Exact match

**Support Strength:** 2.4/8
  - (+) `final_answer`: "overclaim"
    _Conclusion grounded by reasoning chain_
  - Note: Support classification: 0 load-bearing, 1 supporting, 0 mentioned / 6
  - Note: Reasoning graph confirms conclusion grounding

**Structural Reasoning:** 5.3/8
  - (+) `steps[4]`: "Applied priority rule: promotional language ('major breakthrough,' 'transform outcomes') indicates overclaim rather than"
    _Most informative reasoning step_
  - Note: 6 reasoning steps
  - Note: Low step utility: 1/6 steps contribute

**Assumption Discipline:** 3.9/6
  - (+) `assumptions[2]`: "The company is claiming cardiovascular protection benefits based solely on biomarker changes"
    _Most substantive assumption_
  - Note: 3/3 substantive assumptions

**Uncertainty Handling:** 3.3/6
  - (+) `uncertainties[0]`: "Whether familial hypercholesterolaemia context changes the strength of LDL-outcome relationship"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - (-) `uncertainties[0]`: "Whether familial hypercholesterolaemia context changes the strength of LDL-outcome relationship"
    _Listed but never addressed in reasoning_
  - (-) `uncertainties[1]`: "Exact regulatory standards for accelerated approval pathways"
    _Listed but never addressed in reasoning_
  - Note: 2 uncertainties (2 substantive)
  - Note: 2 decorative uncertainty(ies)

**Alternative Hypothesis Quality:** 4.5/6
  - (+) `alternative_hypotheses[1]`: "solid - if focusing only on LDL reduction claim without cardiovascular implications"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 genuinely diverse alternatives

**Self Monitoring Quality:** 1.6/8
  - (+) `self_check[2]`: "Did not overflag - the promotional language clearly exceeds the biomarker evidence"
    _Most substantive self-verification step_
  - (-) `self_check[0]`: "Confirmed promotional language justifies overclaim classification"
    _Fluff self-check_
  - Note: 3 self-check items
  - Note: Self-check quality: 0 deep, 1 arithmetic, 2 fluff

**Mechanism Quality:** 0.0/10
  - Note: Neither names concept nor explains mechanism

**Communication Efficiency:** 10.0/10
  - Note: Signal density: 0.85, 206 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Sonnet

**MODERATE:**
- **Missed Key Insight** `[MEDIUM CONFIDENCE]`: Missed expected finding: unsupported_generalization
  - `(task expectation)`: "Expected: unsupported_generalization"
  - _Impacts: insight_depth_

**STYLISTIC:**
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Whether familial hypercholesterolaemia context changes the s...' is listed but not addressed
  - `uncertainties[0]`: "Whether familial hypercholesterolaemia context changes the strength of LDL-outcome relationship"
  - _Impacts: uncertainty_handling_
- **Decorative Uncertainty** `[HEURISTIC]`: Uncertainty 'Exact regulatory standards for accelerated approval pathways...' is listed but not addressed
  - `uncertainties[1]`: "Exact regulatory standards for accelerated approval pathways"
  - _Impacts: uncertainty_handling_


## Consistency & Grounding Audit

### Claude Sonnet

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/11 content words)
  - `key_claims[0]`: "Company actively promotes 'major breakthrough in cardiovascular protection' based on 12-week biomark"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/10 content words)
  - `key_claims[1]`: "Claims about transforming outcomes for heart attack/stroke prevention exceed evidence from LDL measu"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/6 content words)
  - `key_claims[2]`: "No cardiovascular outcomes were measured to support cardiovascular protection claims"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 1 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[0]`: "Whether familial hypercholesterolaemia context changes the strength of LDL-outcome relationship"
- **[WARN]** `[HEURISTIC]` `decorative_uncertainty`: Uncertainty 2 appears decorative — not addressed in reasoning or self-check
  - `uncertainties[1]`: "Exact regulatory standards for accelerated approval pathways"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 1 is stated without rejection reasoning
  - `alternative_hypotheses[0]`: "mechanism_vs_evidence - could classify as evidence tier mismatch"
- **[NOTE]** `[HEURISTIC]` `weak_alternative`: Alternative hypothesis 2 is stated without rejection reasoning
  - `alternative_hypotheses[1]`: "solid - if focusing only on LDL reduction claim without cardiovascular implications"


## Agent Profiles

### Claude Sonnet (claude-sonnet-4-20250514)
**Parse OK:** True | **Latency:** 10741ms

**Final Answer:** overclaim

**Confidence:** 0.92

**Assumptions:**
- The Phase 2 trial only measured LDL cholesterol reduction and liver safety
- No cardiovascular outcomes were measured in this 12-week trial
- The company is claiming cardiovascular protection benefits based solely on biomarker changes

**Reasoning Steps:**
1. Identified evidence tier: biomarker study measuring LDL cholesterol reduction over 12 weeks
2. Identified conclusion tier: company claims about cardiovascular protection and transforming outcomes for heart attack/stroke prevention
3. Found active promotional language: 'major breakthrough in cardiovascular protection' and 'transform outcomes'
4. Noted the evidence-conclusion gap: biomarker changes vs. clinical outcomes
5. Applied priority rule: promotional language ('major breakthrough,' 'transform outcomes') indicates overclaim rather than mechanism_vs_evidence
6. Confirmed no direct cardiovascular outcome evidence supports the cardiovascular protection claims

**Key Claims:**
- Company actively promotes 'major breakthrough in cardiovascular protection' based on 12-week biomarker data
- Claims about transforming outcomes for heart attack/stroke prevention exceed evidence from LDL measurements
- No cardiovascular outcomes were measured to support cardiovascular protection claims

**Alternative Hypotheses:**
- mechanism_vs_evidence - could classify as evidence tier mismatch
- solid - if focusing only on LDL reduction claim without cardiovascular implications

**Uncertainties:**
- Whether familial hypercholesterolaemia context changes the strength of LDL-outcome relationship
- Exact regulatory standards for accelerated approval pathways

**Self-Verification:**
- Confirmed promotional language justifies overclaim classification
- Verified no cardiovascular outcome data supports cardiovascular claims
- Did not overflag - the promotional language clearly exceeds the biomarker evidence

**Dimension Scores:**
- Correctness: 30.0/30 `##########`
- Support Strength: 2.4/8 `###.......`
- Structural Reasoning: 5.3/8 `######....`
- Assumption Discipline: 3.9/6 `######....`
- Uncertainty Handling: 3.3/6 `#####.....`
- Alternative Hypothesis Quality: 4.5/6 `#######...`
- Self Monitoring Quality: 1.6/8 `##........`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 0.0/10 `..........`
- Communication Efficiency: 10.0/10 `##########`


## Final Verdict

**Solo run: Claude Sonnet** scored **69.0/100**.

**Best per dimension:**
- Correctness: Claude Sonnet (30.0/30)
- Support Strength: Claude Sonnet (2.4/8)
- Structural Reasoning: Claude Sonnet (5.3/8)
- Assumption Discipline: Claude Sonnet (3.9/6)
- Uncertainty Handling: Claude Sonnet (3.3/6)
- Alternative Hypothesis Quality: Claude Sonnet (4.5/6)
- Self Monitoring Quality: Claude Sonnet (1.6/8)
- Insight Depth: Claude Sonnet (8.0/8)
- Mechanism Quality: Claude Sonnet (0.0/10)
- Communication Efficiency: Claude Sonnet (10.0/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Sonnet | 10.7s | 69.0/100 | 6.4 |

Failure modes observed: decorative_uncertainty, missed_key_insight.
